» Articles » PMID: 3063114

Structural Manifestations of Diabetic Cardiomyopathy in the Rat and Its Reversal by Insulin Treatment

Overview
Journal Am J Anat
Date 1988 Jul 1
PMID 3063114
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The structural effects of diabetes and subsequent insulin treatment upon the contractile and supporting elements of the rat myocardium were examined at progressive stages of both untreated and treated disease. Diabetes was induced by intravenous injection of alloxan, and tissue was examined after 6, 12, and 26 weeks. Insulin treatment began after 12 weeks of diabetes and tissue from these animals was examined after the same intervals. Within the cardiocytes, diabetes produced a focal yet progressive loss of myofibrils, transverse tubules, and sarcoplasmic reticulum, and separation of the fasciae adherens was evident at the intercalated disk. Mitochondrial damage was not evident. These cytoplasmic alterations were accompanied by intercellular and perivascular deposition of connective tissue, thickening of the endothelial cytoplasm with pinocytotic hyperactivity, and characteristic basal laminar changes. When insulin treatment began after 12 weeks of diabetes, most, but not all, of these changes were reversed, and this reversal was essentially complete within 6-12 weeks. Even with longer periods of insulin treatment, cardiocytes still exhibited scattered areas of myofibril loss and extracellular matrix was retained. In contrast, diabetic changes in the intercalated disk and capillaries, including their basal laminae, were completely and rapidly reversed. It is hypothesized that the structural manifestations of diabetic cardiomyopathy consist of two major components; the first is a short-term, physiologic adaptation to metabolic alterations, while the other represents degenerative changes for which the myocardium has only a limited capacity for repair.

Citing Articles

Rhein alleviates advanced glycation end products (AGEs)-induced inflammatory injury of diabetic cardiomyopathy in vitro and in vivo models.

Zhao S, Zhao H, Wang B, Shao C, Pan W, Li S J Nat Med. 2023; 77(4):898-915.

PMID: 37598111 DOI: 10.1007/s11418-023-01741-7.


Effects of altered cellular ultrastructure on energy metabolism in diabetic cardiomyopathy: an study.

Ghosh S, Guglielmi G, Orfanidis I, Spill F, Hickey A, Hanssen E Philos Trans R Soc Lond B Biol Sci. 2022; 377(1864):20210323.

PMID: 36189807 PMC: 9527921. DOI: 10.1098/rstb.2021.0323.


Left ventricular subclinical myocardial dysfunction in uncomplicated type 2 diabetes mellitus is associated with impaired myocardial perfusion: a contrast-enhanced cardiovascular magnetic resonance study.

Liu X, Yang Z, Gao Y, Xie L, Jiang L, Hu B Cardiovasc Diabetol. 2018; 17(1):139.

PMID: 30373588 PMC: 6206833. DOI: 10.1186/s12933-018-0782-0.


Diagnostic approaches for diabetic cardiomyopathy.

Lorenzo-Almoros A, Tunon J, Orejas M, Cortes M, Egido J, Lorenzo O Cardiovasc Diabetol. 2017; 16(1):28.

PMID: 28231848 PMC: 5324262. DOI: 10.1186/s12933-017-0506-x.


Effects of the start time of glycemic control on erectile function in streptozotocin-induced diabetic rats.

Kwon O, Cho S, Paick J, Kim S Int J Impot Res. 2016; 29(1):23-29.

PMID: 27654033 DOI: 10.1038/ijir.2016.39.